The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Acute myeloid leukemia: 2019 update on risk‐stratification and management
Abstract
Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason patients are not cured is resistance to treatment, often manifested as relapse from remission, rather than, even in older patients, TRM, whose incidence is decreasing. Knowledge of the pre‐treatment mutation status of various genes has improved our ability to assign initial treatment and, of particular importance, knowledge of whether patients ostensibly in remission have measurable residual disease should influence subsequent management. Several new drugs have been approved by the FDA and we discuss their role in treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationGenomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
Gooley, T. A., Chien, J. W., Pergam, S. A., Hingorani, S., Sorror, M. L., Boeckh, M., Martin, P. J., Sandmaier, B. M., Marr, K. A., Appelbaum, F. R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004383 · Cited by 1,493
Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716984 · Cited by 1,454
Age and acute myeloid leukemia
Appelbaum, F. R., Gundacker, H., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,350
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Schuurhuis, G. J., Heuser, M., Freeman, S., Béné, M.-C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T., Hills, R. K., Hourigan, C. S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-801498 · Cited by 1,041
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6112 · Cited by 1,025
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991
Juliusson, G., Antunovic, P., Derolf, Å., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wahlin, A., & Höglund, M. (2009) · Blood · doi:10.1182/blood-2008-07-172007 · Cited by 987
Assessment of Minimal Residual Disease in Standard-Risk AML
Ivey, A., Hills, R. K., Simpson, M. A., Jovanovic, J. V., Gilkes, A., Grech, A., Patel, Y., Bhudia, N., Farah, H., Mason, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507471 · Cited by 845
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Jongen-Lavrencic, M., Grob, T., Hanekamp, D., Kavelaars, F. G., al Hinai, A., Zeilemaker, A., Erpelinck-Verschueren, C. A. J., Gradowska, P. L., Meijer, R., Cloos, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716863 · Cited by 786
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
Self-citationScott, B. L., Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7091 · Cited by 667
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Bhatt, V., Bixby, D., Blum, W., Coutre, S. E., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0116 · Cited by 654
Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations
Salk, J. J., Schmitt, M. W., & Loeb, L. A. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.117 · Cited by 541
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Breems, D. A., Van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., De Greef, G. E., Jacky, E., Van der Lelie, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.027 · Cited by 511
Stein, E. M., Garcia-Manero, G., Rizzieri, D. A., Tibes, R., Berdeja, J. G., Savona, M. R., Jongen-Lavrenic, M., Altman, J. K., Thomson, B., Blakemore, S. J., et al. (2018) · Blood · doi:10.1182/blood-2017-12-818948 · Cited by 461
Larson, R. A., Sievers, E. L., Stadtmauer, E. A., Löwenberg, B., Estey, E. H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J. M., Richie, M., et al. (2005) · Cancer · doi:10.1002/cncr.21326 · Cited by 460
Self-citationCord-Blood Transplantation in Patients with Minimal Residual Disease
Milano, F., Gooley, T., Wood, B., Woolfrey, A., Flowers, M. E., Doney, K., Witherspoon, R., Mielcarek, M., Deeg, J. H., Sorror, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602074 · Cited by 443
Terwijn, M., van Putten, W. L. J., Kelder, A., van der Velden, V. H. J., Brooimans, R. A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G. E., Valk, P. J. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9628 · Cited by 442
DiNardo, C. D., Rausch, C. R., Benton, C., Kadia, T., Jain, N., Pemmaraju, N., Daver, N., Covert, W., Marx, K. R., Mace, M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25000 · Cited by 424
Sorror, M. L., Storb, R. F., Sandmaier, B. M., Maziarz, R. T., Pulsipher, M. A., Maris, M. B., Bhatia, S., Ostronoff, F., Deeg, H. J., Syrjala, K. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8157 · Cited by 423
Self-citationRöllig, C., Serve, H., Hüttmann, A., Noppeney, R., Müller-Tidow, C., Krug, U., Baldus, C. D., Brandts, C. H., Kunzmann, V., Einsele, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00362-9 · Cited by 401
Araki, D., Wood, B. L., Othus, M., Radich, J. P., Halpern, A. B., Zhou, Y., Mielcarek, M., Estey, E. H., Appelbaum, F. R., & Walter, R. B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3826 · Cited by 400
Self-citationJourdan, E., Boissel, N., Chevret, S., Delabesse, E., Renneville, A., Cornillet, P., Blanchet, O., Cayuela, J.-M., Recher, C., Raffoux, E., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462879 · Cited by 363
Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0060 · Cited by 362
Hematopoietic stem cell transplantation for patients with AML in first complete remission
Cornelissen, J. J., & Blaise, D. (2016) · Blood · doi:10.1182/blood-2015-07-604546 · Cited by 346
Zhu, H.-H., Zhang, X.-H., Qin, Y.-Z., Liu, D.-H., Jiang, H., Chen, H., Jiang, Q., Xu, L.-P., Lu, J., Han, W., et al. (2013) · Blood · doi:10.1182/blood-2012-11-468348 · Cited by 327
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Walter, R. B., Appelbaum, F. R., Estey, E. H., & Bernstein, I. D. (2012) · Blood · doi:10.1182/blood-2011-11-325050 · Cited by 321
Self-citationFreeman, S. D., Virgo, P., Couzens, S., Grimwade, D., Russell, N., Hills, R. K., & Burnett, A. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1753 · Cited by 317
Serve, H., Krug, U., Wagner, R., Sauerland, M. C., Heinecke, A., Brunnberg, U., Schaich, M., Ottmann, O., Duyster, J., Wandt, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4990 · Cited by 313
Feldman, E. J., Lancet, J. E., Kolitz, J. E., Ritchie, E. K., Roboz, G. J., List, A. F., Allen, S. L., Asatiani, E., Mayer, L. D., Swenson, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5961 · Cited by 310
How I treat refractory and early relapsed acute myeloid leukemia
Thol, F., Schlenk, R. F., Heuser, M., & Ganser, A. (2015) · Blood · doi:10.1182/blood-2014-10-551911 · Cited by 303
Muffly, L., Pasquini, M. C., Martens, M., Brazauskas, R., Zhu, X., Adekola, K., Aljurf, M., Ballen, K. K., Bajel, A., Baron, F., et al. (2017) · Blood · doi:10.1182/blood-2017-03-772368 · Cited by 297
Age-related clonal hematopoiesis
Shlush, L. I. (2018) · Blood · doi:10.1182/blood-2017-07-746453 · Cited by 281
Medeiros, B. C., Satram-Hoang, S., Hurst, D., Hoang, K. Q., Momin, F., & Reyes, C. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2351-x · Cited by 259
Chen, X., Xie, H., Wood, B. L., Walter, R. B., Pagel, J. M., Becker, P. S., Sandhu, V. K., Abkowitz, J. L., Appelbaum, F. R., & Estey, E. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3518 · Cited by 257
Self-citationCrenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Galanis, A., Ma, H., Rajkhowa, T., Ramachandran, A., Small, D., Cortes, J., & Levis, M. (2014) · Blood · doi:10.1182/blood-2013-10-529313 · Cited by 252
Comprehensive mutational profiling of core binding factor acute myeloid leukemia
Duployez, N., Marceau-Renaut, A., Boissel, N., Petit, A., Bucci, M., Geffroy, S., Lapillonne, H., Renneville, A., Ragu, C., Figeac, M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-688705 · Cited by 250
Kröger, N., Iacobelli, S., Franke, G.-N., Platzbecker, U., Uddin, R., Hübel, K., Scheid, C., Weber, T., Robin, M., Stelljes, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7349 · Cited by 250
Estey, E., Thall, P., Beran, M., Kantarjian, H., Pierce, S., & Keating, M. (1997) · Blood · doi:10.1182/blood.v90.8.2969 · Cited by 229
Self-citationLo-Coco, F. (2004) · Blood · doi:10.1182/blood-2004-04-1550 · Cited by 225
Quintás-Cardama, A., Ravandi, F., Liu-Dumlao, T., Brandt, M., Faderl, S., Pierce, S., Borthakur, G., Garcia-Manero, G., Cortes, J., & Kantarjian, H. (2012) · Blood · doi:10.1182/blood-2012-06-436055 · Cited by 218
Sekeres, M. A., Elson, P., Kalaycio, M. E., Advani, A. S., Copelan, E. A., Faderl, S., Kantarjian, H. M., & Estey, E. (2009) · Blood · doi:10.1182/blood-2008-05-157065 · Cited by 216
Self-citationLeukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
Terwijn, M., Zeijlemaker, W., Kelder, A., Rutten, A. P., Snel, A. N., Scholten, W. J., Pabst, T., Verhoef, G., Löwenberg, B., Zweegman, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107587 · Cited by 215
Burnett, A. K., Goldstone, A., Hills, R. K., Milligan, D., Prentice, A., Yin, J., Wheatley, K., Hunter, A., & Russell, N. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5977 · Cited by 207
Freeman, S. D., Hills, R. K., Virgo, P., Khan, N., Couzens, S., Dillon, R., Gilkes, A., Upton, L., Nielsen, O. J., Cavenagh, J. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.3425 · Cited by 201
Roboz, G. J., Rosenblat, T., Arellano, M., Gobbi, M., Altman, J. K., Montesinos, P., O'Connell, C., Solomon, S. R., Pigneux, A., Vey, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.8562 · Cited by 198
Fathi, A. T., DiNardo, C. D., Kline, I., Kenvin, L., Gupta, I., Attar, E. C., Stein, E. M., de Botton, S., & for the AG221-C-001 Study Investigators (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4695 · Cited by 195
Genetic predisposition to hematologic malignancies: management and surveillance
Godley, L. A., & Shimamura, A. (2017) · Blood · doi:10.1182/blood-2017-02-735290 · Cited by 190
How I diagnose and manage individuals at risk for inherited myeloid malignancies
The University of Chicago Hematopoietic Malignancies Cancer Risk Team (2016) · Blood · doi:10.1182/blood-2016-05-670240 · Cited by 182
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
Morita, K., Kantarjian, H. M., Wang, F., Yan, Y., Bueso-Ramos, C., Sasaki, K., Issa, G. C., Wang, S., Jorgensen, J., Song, X., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6757 · Cited by 180
Daver, N., Boddu, P., Garcia-Manero, G., Yadav, S. S., Sharma, P., Allison, J., & Kantarjian, H. (2018) · Leukemia · doi:10.1038/s41375-018-0070-8 · Cited by 179
Sorror, M. L., Storer, B. E., Fathi, A. T., Gerds, A. T., Medeiros, B. C., Shami, P., Brunner, A. M., Sekeres, M. A., Mukherjee, S., Peña, E., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2714 · Cited by 177
Self-citationOthus, M., Kantarjian, H., Petersdorf, S., Ravandi, F., Godwin, J., Cortes, J., Pierce, S., Erba, H., Faderl, S., Appelbaum, F. R., et al. (2014) · Leukemia · doi:10.1038/leu.2013.176 · Cited by 167
Self-citationGallipoli, P., Giotopoulos, G., Tzelepis, K., Costa, A. S. H., Vohra, S., Medina-Pérez, P., Basheer, F., Marando, L., Lisio, L. D., Dias, J. M. L., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820035 · Cited by 166
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2012-07-444851 · Cited by 165
Lamba, J. K., Chauhan, L., Shin, M., Loken, M. R., Pollard, J. A., Wang, Y.-C., Ries, R. E., Aplenc, R., Hirsch, B. A., Raimondi, S. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2513 · Cited by 159
Schlenk, R. F., Taskesen, E., van Norden, Y., Krauter, J., Ganser, A., Bullinger, L., Gaidzik, V. I., Paschka, P., Corbacioglu, A., Göhring, G., et al. (2013) · Blood · doi:10.1182/blood-2013-05-503847 · Cited by 155
Getta, B. M., Devlin, S. M., Levine, R. L., Arcila, M. E., Mohanty, A. S., Zehir, A., Tallman, M. S., Giralt, S., & Roshal, M. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.03.017 · Cited by 143
Craddock, C., Labopin, M., Robin, M., Finke, J., Chevallier, P., Yakoub‐Agha, I., Bourhis, J. H., Sengeløv, H., Blaise, D., Luft, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140996 · Cited by 142
Ostronoff, F., Othus, M. K. D., Lazenby, M., Estey, E. H., Appelbaum, F. R., Evans, A., Godwin, J. E., Gilkes, A., Kopecky, K. J., Burnett, A. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0571 · Cited by 137
Self-citationLee, S. J., Logan, B. R., Westervelt, P., Cutler, C. S., Woolfrey, A. E., Khan, S. P., Waller, E. K., Maziarz, R. T., Wu, J., Shaw, B. E., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2520 · Cited by 135
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Wei, A. H., & Tiong, I. S. (2017) · Blood · doi:10.1182/blood-2017-08-784066 · Cited by 130
Bertoli, S., Bérard, E., Huguet, F., Huynh, A., Tavitian, S., Vergez, F., Dobbelstein, S., Dastugue, N., Mas, V. M., Delabesse, É., et al. (2013) · Blood · doi:10.1182/blood-2012-09-454553 · Cited by 124
Wong, T. N., Miller, C. A., Klco, J. M., Petti, A. A., Demeter, R., Helton, N., Li, T., Fulton, R. S., Heath, S. E., Mardis, E. R., et al. (2015) · Blood · doi:10.1182/blood-2015-10-677021 · Cited by 111
Paschka, P., Schlenk, R. F., Weber, D., Benner, A., Bullinger, L., Heuser, M., Gaidzik, V. I., Thol, F. R., Agrawal, M., Teleanu, V., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0129-6 · Cited by 107
Ravandi, F., Cortes, J. E., Faderl, S., et al. (2010) · Blood · doi:10.1182/blood-2010-07-296392 · Cited by 106
Takahashi, K., Patel, K. P., Bueso-Ramos, C., Zhang, J., Gumbs, C. E., Jabbour, E. J., Kadia, T. M., Andreff, M., Konopleva, M. Y., Dinardo, C. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7290 · Cited by 105
Eisfeld, A., Kohlschmidt, J., Mrózek, K., Blachly, J. S., Walker, C. J., Nicolet, D., Orwick, S. J., Maharry, S. E., Carroll, A. J., Stone, R. M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0068-2 · Cited by 99
Löwenberg, B., Pabst, T., Maertens, J. A., van Norden, Y., Biemond, B. J., Schouten, H. C., Spertini, O., Vellenga, E., Graux, C., Havelange, V., et al. (2017) · Blood · doi:10.1182/blood-2016-10-740613 · Cited by 98
Nardi, V., Winkfield, K. M., Ok, C. Y., Niemierko, A., Kluk, M., Attar, E. C., Garcia‐Manero, G., Wang, S. A., & Hasserjian, R. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7340 · Cited by 94
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML
Patel, S. S., Kuo, F. C., Gibson, C. J., Steensma, D. P., Soiffer, R. J., Alyea, E. P., Chen, Y.-B. A., Fathi, A. T., Graubert, T. A., Brunner, A. M., et al. (2018) · Blood · doi:10.1182/blood-2018-01-828467 · Cited by 88
Investigational CD33-targeted therapeutics for acute myeloid leukemia
Walter, R. B. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1452911 · Cited by 87
Estey, E. H., Levine, R. L., & Löwenberg, B. (2015) · Blood · doi:10.1182/blood-2015-01-561373 · Cited by 85
Self-citationBello, C. M., Yu, D., Komrokji, R. S., Zhu, W., Wetzstein, G. A., List, A. F., & Lancet, J. E. (2010) · Cancer · doi:10.1002/cncr.25598 · Cited by 82
Othus, M. K. D., Wood, B. L., Stirewalt, D. L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.120 · Cited by 80
Wheatley, K. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyg313 · Cited by 74
Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation
Elsawy, M., & Sorror, M. L. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.141 · Cited by 74
Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia
Jurcic, J. G., & Rosenblat, T. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e126 · Cited by 72
Lazenby, M., Gilkes, A., Marrin, C., Evans, A., Hills, R. K., & Burnett, A. K. (2014) · Leukemia · doi:10.1038/leu.2014.90 · Cited by 63
Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia
Halpern, A. B., Lyman, G. H., Walsh, T. J., Kontoyiannis, D. P., & Walter, R. B. (2015) · Blood · doi:10.1182/blood-2015-07-627323 · Cited by 62
Itzykson, R., Duployez, N., Fasan, A., Decool, G., Marceau‐Renaut, A., Meggendorfer, M., Jourdan, É., Petit, A., Lapillonne, H., Micol, J., et al. (2018) · Blood · doi:10.1182/blood-2018-03-837781 · Cited by 62
Immunotherapy for Acute Myeloid Leukemia
Lichtenegger, F. S., Krupka, C., Köhnke, T., & Subklewe, M. S. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.006 · Cited by 60
Boddu, P. C., Kantarjian, H. M., Ravandi, F., Garcia‐Manero, G., Verstovšek, S., Jabbour, E. J., Takahashi, K., Bhalla, K. N., Konopleva, M. Y., Dinardo, C. D., et al. (2017) · Cancer · doi:10.1002/cncr.30704 · Cited by 60
Jaramillo, S., Benner, A., Krauter, J., Martin, H., Kindler, T., Bentz, M., Salih, H. R., Held, G., Köhne, C.-H., Götze, K. S. S., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.45 · Cited by 60
Kuo, F. C., Mar, B. G., Lindsley, R. C., & Lindeman, N. I. (2017) · Blood · doi:10.1182/blood-2017-03-734533 · Cited by 58
Wei, A. H., Strickland, S. A., Roboz, G. J., Hou, J., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A. K., Chyla, B., Popovic, R., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.890.890 · Cited by 58
Laszlo, G. S., Harrington, K. H., Gudgeon, C. J., Beddoe, M. E., Fitzgibbon, M., Ries, R. E., Lamba, J. K., McIntosh, M. W., Meshinchi, S., & Walter, R. B. (2016) · Oncotarget · doi:10.18632/oncotarget.9674 · Cited by 57
Krug, U. O., Berdel, W. E., Gale, R. P., Haferlach, C., Schnittger, S., Müller‐Tidow, C., Braess, J., Spiekermann, K., Staib, P., Beelen, D. W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.25 · Cited by 56
Harada, Y., Nagata, Y., Kihara, R., Ishikawa, Y., Asou, N., Ohtake, S., Miyawaki, S., Sakura, T., Ozawa, Y., Usui, N., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.01.008 · Cited by 52
Halpern, A. B., Othus, M. K. D., Huebner, E. M., Scott, B. L., Becker, P. S., Percival, M. M., Hendrie, P. C., Gardner, K. M., Chen, T. L., Buckley, S. A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0135-8 · Cited by 49
Self-citationCord-Blood Transplantation in Patients with Minimal Residual Disease
Hourigan, C. S., Haferlach, T., & Hokland, P. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1612872 · Cited by 48
Mawad, R., Gooley, T. A., Sandhu, V. K., Lionberger, J. M., Scott, B. L., Sandmaier, B. M., O’Donnell, P. V., Becker, P. S., Petersdorf, S. H., Dorcy, K. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.2567 · Cited by 46
Self-citationBoddu, P. C., Jorgensen, J. L., Kantarjian, H. M., Borthakur, G. M., Kadia, T. M., Daver, N. G., Alvarado, Y., Pemmaraju, N., Bose, P., Naqvi, K., et al. (2017) · Leukemia · doi:10.1038/leu.2017.285 · Cited by 46
Bravo, G. M., Huang, X., Jabbour, E. J., Borthakur, G. M., Dinardo, C. D., Pemmaraju, N., Cortes, J. E., Verstovšek, S., Kadia, T. M., Daver, N. G., et al. (2016) · Leukemia · doi:10.1038/leu.2016.303 · Cited by 44
Self-citationØstgård, L. S. G., Nørgaard, M., Medeiros, B. C., Friis, L. S., Schöllkopf, C., Severinsen, M. T., Marcher, C. W., & Nørgaard, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6728 · Cited by 42
How good are we at predicting the fate of someone with acute myeloid leukaemia?
Estey, E. H., & Gale, R. P. (2017) · Leukemia · doi:10.1038/leu.2017.56 · Cited by 36
Self-citationØstgård, L. S. G., Lund, J. L., Nørgaard, J. M., Nørgaard, M., Medeiros, B. C., Nielsen, B., Nielsen, O. J., Overgaard, U. M., Kallenbach, M., Marcher, C. W., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.10.019 · Cited by 33
Kantarjian, H. M., Dinardo, C. D., Nogueras‐González, G. M., Kadia, T. M., Jabbour, E. J., Bueso-Ramos, C., O'Brien, S. M., Konopleva, M. Y., Jain, N. B., Daver, N. G., et al. (2018) · Cancer · doi:10.1002/cncr.31370 · Cited by 30
Nikanjam, M., Capparelli, E. V., Lancet, J. E., Louie, A. C., & Schiller, G. J. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3484-5 · Cited by 28
Tsai, S. B., Rhodes, J. M., Liu, H., Shore, T. B., Bishop, M. R., Cushing, M. M., Gergis, U. S., Godley, L. A., Kline, J. P., Larson, R. A., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.794 · Cited by 25
Lancet, J. E., Hoering, A., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D. E., et al. (2016) · Blood · doi:10.1182/blood.v128.22.906.906 · Cited by 20
Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine
Desoutter, J., Gay, J., Berthon, C., Adès, L., Gruson, B., Geffroy, S., Plantier, I., Marceau‐Renaut, A., Hélevaut, N., Fernandes, J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.314 · Cited by 17
Acute myeloid leukemia therapy and the chosen people
Estey, E. H., & Gale, R. P. (2016) · Leukemia · doi:10.1038/leu.2016.306 · Cited by 13
Self-citationNew drugs in AML: uses and abuses
Estey, E. H., Gale, R. P., & Sekeres, M. A. (2018) · Leukemia · doi:10.1038/s41375-018-0168-z · Cited by 13
Self-citationØstgård, L. S. G., Nørgaard, M., Medeiros, B. C., Severinsen, M. T., Friis, L. S., Marcher, C. W., Schöllkopf, C., & Nørgaard, J. M. (2018) · Blood · doi:10.1182/blood-2017-11-814327 · Cited by 11
Walter, M. J. (2015) · Blood · doi:10.1182/blood-2015-01-621193 · Cited by 6
Cited by
DiNardo, C. D., Lachowiez, C. A., Takahashi, K., Loghavi, S., Xiao, L., Kadia, T., Daver, N., Adeoti, M., Short, N. J., Sasaki, K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03736 · Cited by 331
Pollyea, D. A., Bixby, D., Perl, A., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., de Lima, M., Fathi, A. T., Foran, J. M., Gojo, I., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0002 · Cited by 320
Pi, L., Rooprai, J., Allan, D., Atkins, H., Bredeson, C., Fulcher, A., Ito, C., Ramsay, T., Shorr, Stanford, W., et al. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106222 · Cited by 25
Metadata
- Authors
- Estey, E. H.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2018-10
- Volume
- 93
- Issue
- 10
- Pages
- 1267-1291
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2915860404
- Cited by
- 371
- References
- 114
- FWCI
- 25.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.